

1. 94042544/14, 20.09.1996.
 2. 60 / II 201-: 19 - 22 2010, .677.
 3. 1 / , 2008 . 21(2), . 35-41.
 4. 48524 /

6 33/76, 6 33/04. u 2009 08934; . 28.08.2009;
 . 2 .0 .20 0, . 6.
 3. Galey F.D., Holstege D.M., Fisher E.G., Toxicosis in dairy cattle to poison hemlock (*Conium maculatum*) in hay: isolation of Conium alkaloids in plants, hay, and urine, *J. Vet. Diagn. Invest.*, 1992, Vol.4, 60 - 64.
 6. Kondoh M, Suzuki I, Nagashima F, Simizu S, Harada M, Fujii M, Osada H, Asakawa Y, Watanabe Y. Kaurene diterpene induces apoptosis in human leukemia cells partly through a caspase-8-dependent pathway. *J Pharmacol Exp Ther* 2004; : -22.
 7. Stephen T. Lee, Benedict T. Green, Kevin D. Welch, James A. Pfister and Kip E. Panter, Stereoselective Potencies and Relative Toxicities of Coniine Enantiomers, *Chem. Res. Toxicol.*, 2008, 2 (0), pp 206 -2064.

30.08.20ii

612.017.2; 621.317

Conium maculatum (Weieda).

Conium - -

M.A. Zabolotny, A.I. Momot, N.V. Bashmakova, O.P. Dmytrenko, M.P. Kulish, G.I. Dovbeshko, G.I. Solyanyk, L.N. Kirkilevskaya, E.P. Gnatyuk, P. Scharf, U. Ritter

MODIFICATION OF PROPERTIES OF ALKALOIDS OF CONIUM MACULATUM D6 (WELEDA)

Key words: Fullerene water solution, nanocomposite, coniium, - coniceine, optical ab-sorption, quantum -chemical calculation, IR - spectra

In this work possibilities of bionanotechnology for the purpose of improvement of ofproperties of medicines are investigated. The interaction of a fullerene water solution with Conium maculatum (Weieda) drug was investigated by the UV - Vis absorption, IR - absorption and quantum -chemical calculation using the density functional theory. It was showed the possibility of formation of a complex between a fullerene molecule and one of the alkaloids of the drug coniium y- coniceine through the breaking the double bond in alkaloid.

582.284.612.017.616-006.04.

GANODERMA LUCIDUM

(Ganode ma lucidum) - « ».

« » 2000 [1].
 « » 365 1.
 » ,

IL-2, G. lucidum [40]. G. lucidum, [2].

IL-2, G. lucidum (G. lucidum, G. lucidum, IL-10, -a, IL-ip, IL-6, IL-2, (GL-B), 10%, 49%, 100%, 200 / . GL-B, 3. lucidum, (p-D- G. lucidum, 180, T - Z, [24]. Ganoderma

LZ-8, in vitro, IL-2, [9]. G. lucidum, [36]., 3p-, -26-

LZ-8, IL-2 [5], in vitro, -5a-, -8,24-, -11-, G. lucidum, -7,22-

LZ-8, LZ-8, PLC/PRF/5, in vitro [34]. G. lucidum, 562

ICAM-1, ILp, ICAM-1, G. lucidum [39]. [4]. [28].

[9]. lucidum, NO, G. lucidum (FTP), Ras-

lucidum. [30]. G. lucidum, p-D-, [26]., 5,8-, -5a,8p-

in vitro in vivo [30]. G. lucidum, [26]., 6,22 - -3p-, G. lucidum, -p-, -a.

(), p-D- RAW 264.7, G. lucidum, [30]., p [20].

NO, NO, lucidum, G. lucidum, [20]., G.

264.7, NO, RAW, [20]., F [20].

NO, L1210, G. lucidum, S-180

NO, G. lucidum, LII, G. lucidum

(D), [8]. (G009) G. lucidum

G009, G009 [17].

G. lucidum -

G. lucidum [IS]. -

-1 NF-kB -

-1 NF-kB. (uPA), -

G. lucidum -1 NF-kB -

G. lucidum uPA, uPAR, -

G. lucidum (FN), (VN), -

uPAuPAR-FN- 1 uPA-uPAR-VN- -

G. lucidum -

[2]. -

1. / [.]. - 2009. - . 11 - 12.
2. 5,6-Dimethylxanthenone-4-acetic acid: a novel biological response modifier for cancer therapy Sh. Zhou, P. Kestell, B. C. Baguley, J. W. Paxton Investig. New Drugs. - 2002. - Vol. 20. - P. 281 - 295.
3. A lectin from mycelia of the fungus *Ganoderma lucidum* / H. Kawagishi, S. Mitsunaga, M. Yamawaki [et al.] Phytochem. - 1997. - Vol. 44. - P. 7 - 10.
4. A mushroom fruiting body-including substance inhibits activities of replicative DNA polymerases Y. Mizushima, L. Hanashima, T. Yamaguchi [etal.]//Biochem. Biophys. Res. Commun. - 1998. - Vol. 249. - P. 17 - 22.
3. A novel T cell mutagen induces cytokine production and upregulation of ICAM-1 expression / M. Haak-Frendscho, K. Kino, T. Sone [et al.]//Cell. Immunol. - 1993. - Vol. 150. - P. 101 - 113.
6. Anti-androgenic activities of the triterpenoids fraction of *Ganoderma lucidum* / J. Liu, K. Shimizu, F. Konishi [et al.]//Food Chem.
7. Antitumor active polysaccharides from the Chinese mushroom *Songshan lingzhi*, the fruiting body of *Ganoderma tsugae* / G. Wang, J. Zhang, T. Mizuno [et al.]//Bioscience, Biotechnology, and Biochemistry. - 1993. - V. 57. - P. 894 - 900.
8. Antitumor activity of the sporoderm-broken germinating spores of *Ganoderma lucidum* X. Liu, J. P. Yuan, C. K. Chung, X. Chen //Cancer Lett. - 2002. - Vol. 182 (2). - P. 155 - 161.
9. A phase I/II study of a *Ganoderma lucidum* (Curt.: Fr.) P. Karst extract (ganopoly) in patients with advanced cancer / Y. Gao, Sh. Zhou, G. Chen [et al.]//Int. J. Med. Mushrooms. - 2002. - Vol. 4 (3). - P. 207 - 214.
10. Applanoxidic acids A, B, C and D, biologically active tetracyclic triterpenes from *Ganoderma applanatum* T. T. Chairul, Y. Hayashi, M. Nishizawa //Phytochemistry. - 1991. - Vol. 30. - P. 4105 - 4109.

G. lucidum -

G1, 21/Waf-1 -

D1. -

G. lucidum -

() JNK (c-Jun N-terminal kinase) -

38 G2. G. lucidum -

12, -

G. lucidum. Erk (ras / extracellular signal-regulated kinase) CREB (cAMP-response element binding protein), G. lucidum -

Erk-1, Erk-2 CREB [13]. -

1. **Ganoderma lucidum** -

2. -

3. -

4. **G. lucidum** -

11. Cao Q. *Ganoderma lucidum* polysaccharides peptide inhibits the growth of vascular endothelial cell and the induction of VEGF in human lung cancer cell / Q. Cao, Z. Lin //Life Sci. - 2006. - Vol. 78. - P. 1457 - 1463.
12. Effects of polysaccharides (F10-c) from mycelium of *Ganoderma tsugae* on proinflammatory cytokine production by THP-1 cells and human PBMC (II) / X. X. Gao, B. X. Wang, X. F. Fei [et al.]//Acta pharmacol. Sinica. - 2000. - Vol. 21. - P. 1186 - 1192.
13. *Ganoderma* extract activates MAP kiases and induces the neuronal differentiation of rat pheochromocytoma PC12 cells / W. M. W. Cheung, W. S. Hui, P. W. K. Chu [et al.]//FEBS Letters. - 2000. - Vol. 486 (3). - P. 291 - 296.
14. *Ganoderma lucidum* causes apoptosis in leukemia, lymphoma and multiple myeloma cells C. I. Muller, T. Kumagai, J. O'Kelly [et al.]//Leukemia Res. - 2006. - Vol. 30. - P. 841 - 848.
15. *Ganoderma lucidum* suppresses angiogenesis through the inhibition of secretion of VEGF and TGF- β 1 from prostate cancer cells / G. Stanley, K. Harvey, V. Slivova [et al.]//Biochem. and Biophys. Res. Commun. - 2005. - Vol. 330, P. 46 - 52.
16. Huie C. W. Chromatographic and electrophoretic methods for *Lingzhi* pharmacologically active components / C. W. Huie, X. Di //J. Chromatogr. B. - 2004. - Vol. 812. - P. 241 - 257.
17. Inhibition of lipid peroxidation and oxidative damage by *Ganoderma lucidum* / J. M. Lee, H. Kwon, H. Jeong [et al.]//Phytother. Res. - 2001. - Vol. 15 (3). - P. 245 - 249.
18. In vitro immunomodulatory effects of ten commonly used herbs on murine lymphocytes C. Wilasrusmee, S. Kittur, J. Siddiqui [et al.] J. Alternat. Complement. Med. - 2002. - Vol. 8 (4). - P. 467 - 475.
19. Kim H. W. Biomedicinal triterpenoids of *Ganoderma lucidum* (Curt.:Fr.) P. Karst (aphyllophoromycetidae) H. W. Kim, B. K. Kim Int. J. Medicinal Mushrooms. -1999. - Vol. 1. - P. 121 -138.
20. Kimura Y. Antitumor and antimetastatic effects on liver triterpenoid fractions of *Ganoderma lucidum*: mechanism of action and isolation of an active substance Y. Kimura, M. Taniguchi, K.

